Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CUE 101

Next Previous
Drug Profile

CUE 101

Alternative Names: CUE-101; LR-19127

Latest Information Update: 09 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cue Biopharma
  • Developer Cue Biopharma; Merck Sharp & Dohme Corp.
  • Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 2 replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Squamous cell cancer

Highest Development Phases

  • Phase II Squamous cell cancer

Most Recent Events

  • 04 Jan 2026 Cue Biopharma completes a phase I trial in Squamous cell cancer (Metastatic disease, Combination therapy, Recurrent, First-line therapy) in USA (IV) (NCT03978689)
  • 15 Sep 2025 Yale University plans a phase II trial in collaboration with Cue Biopharma and National Cancer Institute (NCI) for Squamous cell carcinoma (Neoadjuvant therapy, Late-stage disease, Monotherapy, Combination therapy, Inoperable/Unresectable) in USA (IV infusion) (NCT07172256)
  • 16 Jul 2025 Updated efficacy data from a phase Ib KEYNOTE-A78 trial in Squamous cell cancer released by Cue Biopharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top